Exane Derivatives Autolus Therapeutics PLC Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Exane Derivatives holds 180 shares of AUTL stock, worth $257. This represents 0.0% of its overall portfolio holdings.
Number of Shares
180
Previous 180
-0.0%
Holding current value
$257
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AUTL
# of Institutions
111Shares Held
130MCall Options Held
0Put Options Held
116K-
Blackstone Inc New York, NY20.5MShares$29.3 Million0.24% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$23.8 Million73.83% of portfolio
-
Deep Track Capital, LP Greenwich, CT14.2MShares$20.3 Million1.47% of portfolio
-
Avoro Capital Advisors LLC New York, NY9.91MShares$14.2 Million0.34% of portfolio
-
Armistice Capital, LLC New York, NY9.2MShares$13.2 Million0.31% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $130M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...